These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 29879966)

  • 1. Effects of a price cut reform on the cost and utilization of antidiabetic drugs in Korea: a national health insurance database study.
    Suh HS; Kim JA; Lee IH
    BMC Health Serv Res; 2018 Jun; 18(1):429. PubMed ID: 29879966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of drug price reduction and prescribing restrictions on expenditures and utilisation of antihypertensive drugs in Korea.
    Yoo KB; Lee SG; Park S; Kim TH; Ahn J; Cho MH; Park EC
    BMJ Open; 2015 Jul; 5(7):e006940. PubMed ID: 26179644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do cost containment policies save money and influence physicians' prescribing behavior? Lessons from South Korea's drug policy for diabetes medication.
    Kang SO; Kim SJ; Park S; Jang SI; Park EC
    Int J Qual Health Care; 2019 Mar; 31(2):96-102. PubMed ID: 29788203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Easy cuts, easy rebound: Drug expenditures with massive price cuts in Korea.
    Kwon HY; Bae S; Choi SE; Park S; Lee EK; Park S; Kim J
    Health Policy; 2019 Apr; 123(4):388-392. PubMed ID: 30503763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost containment interventions introduced on the community drugs schemes in Ireland-evaluation of expenditure trends using a national prescription claims database.
    Usher C; Tilson L; Bennett K; Barry M
    Clin Ther; 2012 Mar; 34(3):632-9. PubMed ID: 22381716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impacts of drug reimbursement reductions on utilization and expenditures of oral antidiabetic medications in Taiwan: an interrupted time series study.
    Hsu JC; Lu CY; Wagner AK; Chan KA; Lai MS; Ross-Degnan D
    Health Policy; 2014 Jun; 116(2-3):196-205. PubMed ID: 24314624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of South Korea's new drug-pricing policy on market competition among off-patent drugs.
    Kwon HY; Kim H; Godman B; Reich MR
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(6):1007-14. PubMed ID: 26394767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. National trends in prescription drug expenditures and projections for 2021.
    Tichy EM; Hoffman JM; Suda KJ; Rim MH; Tadrous M; Cuellar S; Clark JS; Wiest MD; Matusiak LM; Schumock GT
    Am J Health Syst Pharm; 2021 Jul; 78(14):1294-1308. PubMed ID: 33880494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Price cuts and drug spending in South Korea: the case of antihyperlipidemic agents.
    Kwon HY; Hong JM; Godman B; Yang BM
    Health Policy; 2013 Oct; 112(3):217-26. PubMed ID: 24075008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effective policy initiatives to constrain lipid-lowering drug expenditure growth in South Korea.
    Bae G; Park C; Lee H; Han E; Kim DS; Jang S
    BMC Health Serv Res; 2014 Mar; 14():100. PubMed ID: 24589172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors Contributing to Increases in Prescription Drug Expenditures Borne by National Health Insurance in South Korea.
    Jo JS; Kim YM; Paek KW; Bea MH; Chun K; Lee S
    Yonsei Med J; 2016 Jul; 57(4):1016-21. PubMed ID: 27189299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of the Price-Volume Agreement Program in South Korea.
    Han E; Park SY; Lee EK
    Health Policy; 2016 Oct; 120(10):1209-1215. PubMed ID: 27519975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of pharmaceutical cost containment policies on doctors' prescribing behavior: Focus on antibiotics.
    Han E; Chae SM; Kim NS; Park S
    Health Policy; 2015 Sep; 119(9):1245-54. PubMed ID: 26119997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [How AMOG limits the supply of diabetes drugs].
    Oberhofer E
    MMW Fortschr Med; 2015 Aug; 157(14):24. PubMed ID: 26289868
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmaceutical reform in South Korea and the lessons it provides.
    Kim HJ; Ruger JP
    Health Aff (Millwood); 2008; 27(4):w260-9. PubMed ID: 18508813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Twenty-year trends in the prescription costs of Type 2 diabetes: Real world data and empirical analysis in Greece.
    Athanasakis K; Prodromiadou E; Papazafiropoulou A; Koutsovasilis A; Driva S; Ziori M; Georgopoulos E; Gougourelas D; Sotiropoulos A; Bousboulas S; Melidonis A; Liatis S
    Diabetes Res Clin Pract; 2020 Apr; 162():108095. PubMed ID: 32112790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of new pricing and copayment schemes for pharmaceuticals in South Korea.
    Lee IH; Bloor K; Hewitt C; Maynard A
    Health Policy; 2012 Jan; 104(1):40-9. PubMed ID: 22000599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Copayment policy effects on healthcare spending and utilization by Korean lung cancer patients at end of life: a retrospective cohort design 2003-2012.
    Kim SJ; Han KT; Park EC; Park S; Kim TH
    Asian Pac J Cancer Prev; 2014; 15(13):5265-70. PubMed ID: 25040986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Impact of China's National Essential Medicine Policy and Its Implications for Urban Outpatients: A Multivariate Difference-in-Differences Study.
    Ding L; Wu J
    Value Health; 2017 Mar; 20(3):412-419. PubMed ID: 28292486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in Type 2 Diabetes Medication Utilization and Costs in the United States, 2014-2019.
    Neilson LM; Munshi KD; Peasah SK; Huang Y; Swart ECS; Henderson R; Manolis C; Good CB
    Med Care; 2021 Sep; 59(9):789-794. PubMed ID: 34183622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.